Die wichtigsten Arbeiten zu.....
Tenofovir (Viread®)
#870 Renal Safety of Highly Active Antiretroviral Therapy including Tenofovir in Vertically HIV-Infected Youths: a 60-Months Longitudinal Study
Vania Giacomet*1, G Bedogni2, V Manfredini1, S Coletto1, F Marinacci1, A
Viganò1, and G Zuccotti1
1Luigi Sacco Hosp, Univ of Milan, Italy and 2Liver Res Ctr, Basovizza, Trieste,
Italy
#871Safety of Highly Active Antiretroviral Therapy Including Tenofovir on Bone Health in Vertically HIV-Infected Youths: a 60-Month Longitudinal Study.
Chiara Cerini*1, S Mora2, G V Zuccotti1, V
Giacomet1, M Puzzovio2, I Zamproni2, S Stucchi1,
S Coletto1, V Manfredini1, and A Vigano1
1Luigi Sacco Hosp, Univ of Milan, Italy and 2San
Raffaele Sci Inst, Milan, Italy
Ennie Chidziva*1, E Zwalango2, E Russell3, H Kizito4, R Nalumenya5, C
Gilks6, K Nathoo1, P Munderi2, D Tumukunde4, D Gibb3, and the DART Trial Team
1Univ of Zimbabwe, Harare; 2Med Res Council/Uganda Virus Res Inst, Entebbe;
3Med Res Council Clin Trials Unit, London, UK; 4Joint Clin Res Ctr, Kampala,
Uganda; 5Infectious Disease Inst, Makerere Univ, Mulago, Uganda; and 6Imperial
Coll London, UK
Kollegen Fragen
